HCQ is a flop, a gimmickSkier59 ... Poor Bunge. He mislead people with his HCQ Kool-Aid, without being able to support his claims with rigorous data.
He thinks that adding zinc and other stuffs makes a difference but if that was the case, they would have been considered in clinical trials, to avoid wasting time, money and patient lifes!
Trump bagholders and Q-Anon members were using HCQ to promote "
the biggest breakthrough in history of medicine"! ... lolllll It couldn't even protect/prevent Trump and Gugliani to get COVID-19! So, so much for "
the biggest breakthrough in history of medicine", especially coming from a a bunch of clowns that don't even believe in rigorous science!
#WhenBungePromotesHCQPeopleDie
Dec. 2: Repurposed Antiviral Drugs for Covid-19 — Interim WHO Solidarity Trial Results | NEJM RESULTS
At 405 hospitals in 30 countries, 11,330 adults underwent randomization; 2750 were assigned to receive remdesivir, 954 to hydroxychloroquine, 1411 to lopinavir (without interferon), 2063 to interferon (including 651 to interferon plus lopinavir), and 4088 to no trial drug. Adherence was 94 to 96% midway through treatment, with 2 to 6% crossover. In total, 1253 deaths were reported (median day of death, day 8; interquartile range, 4 to 14). The Kaplan–Meier 28-day mortality was 11.8% (39.0% if the patient was already receiving ventilation at randomization and 9.5% otherwise). Death occurred in 301 of 2743 patients receiving remdesivir and in 303 of 2708 receiving its control (rate ratio, 0.95; 95% confidence interval [CI], 0.81 to 1.11; P=0.50), in 104 of 947 patients receiving hydroxychloroquine and in 84 of 906 receiving its control (rate ratio, 1.19; 95% CI, 0.89 to 1.59; P=0.23), in 148 of 1399 patients receiving lopinavir and in 146 of 1372 receiving its control (rate ratio, 1.00; 95% CI, 0.79 to 1.25; P=0.97), and in 243 of 2050 patients receiving interferon and in 216 of 2050 receiving its control (rate ratio, 1.16; 95% CI, 0.96 to 1.39; P=0.11). No drug definitely reduced mortality, overall or in any subgroup, or reduced initiation of ventilation or hospitalization duration.
...
All active treatment ended within 14 days, and the numbers of deaths during this 14-day period with any cardiac cause mentioned on the electronic death record were seven with remdesivir and eight with its control, four with hydroxychloroquine and two with its control, six with lopinavir and three with its control, and six with interferon and eight with its control ...
For hydroxychloroquine and lopinavir, the Solidarity trial showed no definite effect on mortality in any subgroup. The only other substantial trial is the Randomized Evaluation of Covid-19 Therapy (RECOVERY) trial,12,13 which for these two drugs was larger than the Solidarity trial and also showed no benefit. Combination of both trials reinforces these null findings (Figs. S19 and S20).
For hydroxychloroquine, the joint rate ratio for death (combining the Solidarity and RECOVERY trials) was 1.10 (95% CI, 0.98 to 1.23), with no apparent benefit whether the patient was receiving ventilation or not. This confidence interval rules out any material benefit from this hydroxychloroquine regimen in hospitalized patients with Covid-19. It is compatible with some adverse effect but is not good evidence for any adverse effect and is not a safety signal. A recent meta-analysis identified 15 small, randomized trials with nonzero mortality14; combining all 17 hydroxychloroquine trials yields a rate ratio of 1.09 (95% CI, 0.98 to 1.21), which still rules out any material benefit.
Dec. 8: Original Research - 8 December 2020
Hydroxychloroquine as Postexposure Prophylaxis to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 Infection
FREE A Randomized Trial
Participants:
Close contacts recently exposed (<96 hours) to persons with diagnosed SARS-CoV-2 infection.
Intervention:
Hydroxychloroquine (400 mg/d for 3 days followed by 200 mg/d for 11 days) or ascorbic acid (500 mg/d followed by 250 mg/d) as a placebo-equivalent control.
Measurements:
Participants self-collected mid-turbinate swabs daily (days 1 to 14) for SARS-CoV-2 polymerase chain reaction (PCR) testing. The primary outcome was PCR-confirmed incident SARS-CoV-2 infection among persons who were SARS-CoV-2 negative at enrollment.
Results:
Between March and August 2020, 671 households were randomly assigned: 337 (407 participants) to the hydroxychloroquine group and 334 (422 participants) to the control group. Retention at day 14 was 91%, and 10 724 of 11 606 (92%) expected swabs were tested. Among the 689 (89%) participants who were SARS-CoV-2 negative at baseline, there was no difference between the hydroxychloroquine and control groups in SARS-CoV-2 acquisition by day 14 (53 versus 45 events; adjusted hazard ratio, 1.10 [95% CI, 0.73 to 1.66]; P > 0.20). The frequency of participants experiencing adverse events was higher in the hydroxychloroquine group than the control group (66 [16.2%] versus 46 [10.9%], respectively; P = 0.026).
Limitation:
The delay between exposure, and then baseline testing and the first dose of hydroxychloroquine or ascorbic acid, was a median of 2 days.
Conclusion:
This rigorous randomized controlled trial among persons with recent exposure excluded a clinically meaningful effect of hydroxychloroquine as postexposure prophylaxis to prevent SARS-CoV-2 infection.